The prevalence of severe refractory asthma Pieter-Paul W. Hekking, MD, Reinier R. Wener, MD, Marijke Amelink, MD, Aelko H. Zwinderman, PhD, Marcel L. Bouvy, MD, PhD, Elisabeth H. Bel, MD, PhD Journal of Allergy and Clinical Immunology Volume 135, Issue 4, Pages 896-902 (April 2015) DOI: 10.1016/j.jaci.2014.08.042 Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Study design: differentiating steps to get to a diagnosis of severe refractory asthma. Journal of Allergy and Clinical Immunology 2015 135, 896-902DOI: (10.1016/j.jaci.2014.08.042) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 2 Results. High-intensity treatment, high-dose ICS (≥1000 μg/d fluticasone equivalent) plus a LABA or medium- to high-dose ICS (500-1000 μg/d fluticasone equivalent) plus daily OCSs plus a prescription for a LABA. Journal of Allergy and Clinical Immunology 2015 135, 896-902DOI: (10.1016/j.jaci.2014.08.042) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions